Investment Analysts’ Recent Ratings Changes for Maplight Therapeutics (MPLT)

A number of research firms have changed their ratings and price targets for Maplight Therapeutics (NASDAQ: MPLT):

• 6/1/2026 – Maplight Therapeutics had its price target raised by Stifel Nicolaus from $28.00 to $36.00. They now have a “buy” rating on the stock.
• 5/28/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 5/26/2026 – Maplight Therapeutics is now covered by UBS Group AG. They set a “buy” rating and a $48.00 price target on the stock.
• 5/26/2026 – Maplight Therapeutics was upgraded by UBS Group AG to “strong-buy”.
• 5/21/2026 – Maplight Therapeutics is now covered by Craig Hallum. They set a “buy” rating and a $43.00 price target on the stock.
• 5/14/2026 – Maplight Therapeutics was upgraded by Lifesci Capital to “strong-buy”.
• 5/4/2026 – Maplight Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $45.00 price target on the stock.
• 5/4/2026 – Maplight Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $45.00 price target on the stock.
• 4/8/2026 – Maplight Therapeutics is now covered by Needham & Company LLC. They set a “buy” rating and a $37.00 price target on the stock.
• 4/7/2026 – Maplight Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.

Insider Activity

In other news, insider Anatol Kreitzer sold 45,422 shares of the stock in a transaction on Monday, April 27th. The stock was sold at an average price of $29.66, for a total transaction of $1,347,216.52. Following the transaction, the insider directly owned 211,190 shares of the company’s stock, valued at $6,263,895.40. This represents a 17.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Woodruff Lillie sold 24,811 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total value of $713,564.36. Following the transaction, the insider directly owned 243,450 shares in the company, valued at $7,001,622. The trade was a 9.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 495,244 shares of company stock worth $14,079,461. Insiders own 3.80% of the company’s stock.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.